Ultragenyx Pharmaceutical | RARE - Pre Tax Profit


Ultragenyx Pharmaceutical reported $-91M in Pre-Tax Profit for its fiscal quarter ending in June of 2026.





Pre Tax Profit Change Date
Acadia Pharmaceuticals USD 46.47M 42.49M Jun/2026
Agios Pharmaceuticals USD -99.11M 9.94M Mar/2026
Alnylam Pharmaceuticals USD 177.81M 43.85M Jun/2026
BioCryst Pharmaceuticals USD 248.02M 235.89M Dec/2025
BioMarin Pharmaceutical USD 141.2M 168.36M Mar/2026
Immunic USD -19.3M 6.28M Dec/2025
Insmed USD -11.37M 150.72M Jun/2026
Ionis Pharmaceuticals USD -114M 21M Jun/2026
Karyopharm Therapeutics USD -22.39M 17.51M Mar/2026
Kyowa Hakko Kirin JPY 23.54B 9.62B Jun/2026
MacroGenics USD -36.77M 21.84M Mar/2026
Moderna USD -1.33B 535M Mar/2026
Neurocrine Biosciences USD 246.8M 7.4M Mar/2026
PTC Therapeutics USD -2.46M 136.62M Mar/2026
Puma Biotechnology USD 20.61M 24.76M Sep/2024
Regeneron Pharmaceuticals USD 1.53B 696.6M Jun/2026
Sarepta Therapeutics USD -1.75M 344.92M Jun/2026
Ultragenyx Pharmaceutical USD -91M 93M Jun/2026
Vertex Pharmaceuticals USD 1.25B 78.1M Mar/2026